Law Offices of Jeffrey D. Slakter
Vioxx®, Celebrex® & Bextra® Attorneys
Toll Free: 866-960-5000 | Main: 214-748-0503
Users of Vioxx®, Celebrex® or Bextra® who have suffered a heart attack, stroke, death or Stevens Johnson skin disease may be entitled to monetary compensation.
We can help you understand your rights and options.
FDA Public Health Advisory: Safety of Vioxx®
Merck & Co., Inc. announced a voluntary withdrawal of Vioxx® from the U.S. market due to safety concerns. Vioxx® is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms. It is also approved for the relief of the signs and symptoms of rheumatoid arthritis in adults and children.
The Agency was informed by Merck & Co., Inc. on September 27, 2004, that the Data Safety Monitoring Board for an ongoing long-term study of Vioxx® (APPROVe) had recommended that the study be stopped early for safety reasons. The study was being conducted in patients at risk for developing recurrent colon polyps. The study showed an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx® compared to placebo, particularly those who had been taking the drug for longer than 18 months. Based on this new safety information, Merck and FDA officials met the next day, September 28, 2004, and during that meeting FDA was informed that Merck was voluntarily withdrawing Vioxx® from the market place.
Attention Celebrex® Consumers:
The FDA declined to comment about whether it will withdraw Celebrex® from the market, but noted that “we do have great concerns about this product and this class of products” (Acting FDA Commissioner Lester Crawford, Wall Street Journal, December 20, 2004). The agency asked Pfizer to pull its advertisements for Celebrex® from television, radio, magazines, and newspapers.
Although Pfizer said it will temporarily remove the Celebrex® ads, the company will continue to sell the drug. It also agreed to inform doctors prescribing Celebrex® that they should consider alternative treatments for patients (FDA Press Release, December 20, 2004).
Attention Bextra® Consumers:
On April 7, 2005, the Food and Drug Administration announced that it had asked Pfizer, Inc. to withdraw Bextra® (valdecoxib) from the market, and that Pfizer had agreed to suspend sales and marketing of Bextra in the U.S. pending further discussions with the agency. The FDA based its decision, in part, on the increased risk of cardiovascular events such as heart attacks and strokes alongside reports of serious and potentially life-threatening skin reactions such as Stevens Johnsons Syndrome and toxic epidermal necrolysis.
Use the form or call the toll free number to begin your free case review today.
Do not discontinue taking your medications without first consulting your doctor.
Law Offices of Jeffrey D. Slakter
Vioxx®, Celebrex® & Bextra® Attorneys
Toll Free: 866-960-5000 | Main: 214-748-0503
The information you obtain at this site is not, nor is it intended to be, legal advice. You should consult an attorney for individual advice regarding your own situation.
Principal Offices in Dallas, Texas
Cases will likely be referred
 | ||||
Free Confidential Consultation
Your Name
E-Mail Address
Phone Number
Alternate Number
Comments
| ||||
Did you or someone you know suffer a heart attack, stroke, death or Stevens Johnson Skin Disease while taking or after taking Vioxx?
Complete form or call now.
